Navigation Links
Sinovac Named to Deloitte Technology Fast 50 China
Date:11/3/2008

eloping Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x9871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington / Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Sinovac to Participate in Two Upcoming Investor Conferences
2. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
3. Sinovac Biotech Holds 2007 Annual General Meeting
4. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
5. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
6. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
7. Sinovac Adjourns Annual General Meeting
8. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
9. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
10. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
11. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- Capitalizing on the continued strong growth ... venture capital market, leaders from BioCrossroads, Eli Lilly ... University, Purdue University, the University of Notre Dame, ... announced the establishment of the INext Fund, a ... Organized through BioCrossroads, Indiana,s initiative to grow, expand ...
(Date:12/16/2009)... biotechnology company,s revenues increase 22% for fiscal 2009; ... 2010 , TORONTO, Dec. 16 /PRNewswire-FirstCall/ - Microbix ... virology and biological technologies, today reported financial results ... fiscal year ended September 30, 2009, Microbix reported ... the same period in 2008. For fourth-quarter 2009, ...
(Date:12/16/2009)... Protocol Assessment with the Food and Drug ... - AEterna Zentaris Inc. (NASDAQ: AEZS ... biopharmaceutical company focused on oncology and endocrine ... partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), ... for perifosine (KRX-0401), the Company,s PI3K/Akt pathway ...
(Date:12/16/2009)... 16 Eppendorf has initiated an,import ... SP systems for,infringement of European patent EP ... the,identification and/or the quantification of a target ... imports of the respective products into any ... required to confiscate any,violating products. , ...
Breaking Biology Technology:Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Microbix' Pipeline Set To Reach Milestones In 2010 2Microbix' Pipeline Set To Reach Milestones In 2010 3Microbix' Pipeline Set To Reach Milestones In 2010 4Microbix' Pipeline Set To Reach Milestones In 2010 5Microbix' Pipeline Set To Reach Milestones In 2010 6Microbix' Pipeline Set To Reach Milestones In 2010 7Microbix' Pipeline Set To Reach Milestones In 2010 8AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5Eppendorf Successfully Initiates Import ban Against Nanosphere, Inc. for the Countries of the European Union 2
... Aug. 5 Orexigen(R) Therapeutics,Inc. (Nasdaq: OREX ), ... system disorders, including obesity, will announce,financial results for its ... 2008, after the markets close. The announcement will be ... p.m. Pacific Time., Orexigen management will host the ...
... Innovations Inc.,(TSX: ATB), a recognized leading developer, manufacturer ... the health and,nutrition industries, today announced that its ... present a company overview,at the upcoming 28th Annual ... 2008 at 11 am (eastern time), in the ...
... NGSX ), a biopharmaceutical company focused on developing ... results for its second quarter 2008 on Wednesday, August ... to review the results will begin at 4:30 p.m. ... be hosted by Anthony DiTonno,President and Chief Executive Officer, ...
Other Biology Technology:Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008 2NeurogesX to Report Second Quarter 2008 Financial Results 2NeurogesX to Report Second Quarter 2008 Financial Results 3
(Date:12/17/2009)... Mark December 10-13, 2010 on your calendar and ... the International Osteoporosis Foundation (IOF). , IOF has ... of Regional Programs that aims to create strong ... member associations. The overall Regional Program includes the ... pleased to announce that the first IOF Regional ...
(Date:12/17/2009)... showing that four commonly used chemotherapy drugs disrupt the ... could be partially reversed with the growth factor IGF-1. ... Cancer Investigation , the University of Rochester Medical Center ... who experience a frustrating decline in cognitive function after ... is not yet clear how our results can be ...
(Date:12/17/2009)... Department of Energy,s Savannah River National Laboratory (SRNL) ... SRNL,s unique Porous Walled Hollow Glass Microspheres available ... and other uses, including applications still being developed. ... years in light-weight filler material, insulation, abrasives and ... unique is the network of interconnected pores in ...
Breaking Biology News(10 mins):UR study reveals chemo's toxicity to brain, possible treatment 2UR study reveals chemo's toxicity to brain, possible treatment 3MO-SCI Corporation to manufacture, market SRNL's unique glass microspheres 2SenesTech Announces New Vice President of Business Development 12862 1SenesTech Announces New Vice President of Business Development 12862 2Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 50490 1Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 50490 2Virginia Mason Signs with Carefx to Implement Fusionfx Solution Suite 50490 3Fighting Multiple Sclerosis One Shirt at a Time 50485 1Fighting Multiple Sclerosis One Shirt at a Time 50485 2
... CAMBRIDGE, Mass. (March 26, 2009) The Howard Hughes ... an Early Career Scientist appointment, a six-year funded position ... , "I am thrilled to receive the HHMI Early ... remarkable history of supporting innovative and creative science, and ...
... MARCH 2009 More than 120 researchers will speak ... life sciences conference to be organized by the European ... 29 August to 1 September 2009. , The ... programmes reflecting the concepts and high-resolution approaches of modern ...
... is available in Spanish . , ... of psychosis and schizophrenia, and those episodes of psychosis ... characteristics, both before their appearance and in the clinical ... conclusions of the doctoral thesis "Neurodevelopment and environmental stress ...
Other Biology News:Whitehead member Peter Reddien named HHMI Early Career Scientist 2Call for abstracts and registration for the EMBO Meeting 2009 2Daily consumption of cannabis predisposes to the appearance of psychosis and schizophrenia 2
Ras-related C3 botulinum toxin substrate 1...
Human sVCAM-1/CD106 ELI-PAIR Kit...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... gene in baculoviral expression vector, transfection ... purification of ten clones, generation of ... clone, protein expression and tag purification ... yield and timeline: 1-4 mg of ...
Biology Products: